CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form...

Full description

Saved in:
Bibliographic Details
Main Authors SATOH, TAKASHI, SANDERS, KRISTEN, SELVARAJ, ANAND, HAO, MING-HONG, REYNOLDS, DOMINIC, MONIZ, GEORGE, WANG, JOHN, PRAJAPATI, SUDEEP, CHANDA, ARANI, YOSHIDA, KENSHI
Format Patent
LanguageEnglish
French
Published 13.06.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided. La présente invention concerne un certain nombre de formes cristallines de N-(2-((6-(3-(2,6-dichloro-3,5-diméthoxy-phényl)-1-méthyluréido)pyrimidine-4-yl)amino)-5-(4-éthylpipérazine-1-yl)phényl)acrylamide. Elles comprennent une forme base libre cristalline, une forme sel monochlorhydrate cristallin, une forme sel dichlorhydrate cristallin, et une forme sel éthanesulfonate cristallin. L'invention concerne également des procédés de fabrication et d'utilisation desdits composés cristallins.
Bibliography:Application Number: CA20162982562